Get the Daily Brief
Latest Biotech News
Biotechnology Legislation and Industry Impact: Reconciliation Bill and ORPHAN Cures Act
Pending U.S. legislative proposals include important biotechnology provisions such as the ORPHAN Cures Act, which addresses rare disease drug pricing and aims to restore incentives for developing...
Microbiome and Cancer: Fusobacterium nucleatum in Colorectal Cancer
Recent comprehensive reviews outline the pathogenic role of Fusobacterium nucleatum in colorectal cancer, including its influence on tumor initiation, progression, metastasis and resistance to...
Vascular Organoids: Rapid Generation via Transcription Factor Activation
A novel method developed by Boston Children's Hospital and Harvard Medical School allows the rapid creation of functional vascular organoids from human stem cells by co-activating endothelial and...
Pharma Budget Bill Drivers: Orphan Drug Wins, Pricing Reforms
Key provisions in the US budget bill under Senate consideration aim to reshape biopharma innovation and pricing. The package proposes reforms to the Inflation Reduction Act's orphan drug...
Anne Wojcicki Secures 23andMe in Nonprofit Takeover Bid
Anne Wojcicki, co-founder and former CEO of 23andMe, won a competitive bidding process to purchase the company for $305 million through her nonprofit, the TTAM Research Institute. The deal...
ADC Therapeutics Restructures: UK Site Closure, Job Cuts
ADC Therapeutics announced the shutdown of its UK research and development site along with a 30% workforce reduction, in a strategic move to concentrate resources on its approved monoclonal...
AI-Generated Science Podcasts Stir Debate Over Traditional Media Future
A recent study in the European Journal of Cardiovascular Nursing explored artificial intelligence's capability to generate scientific podcasts using tools like Google NotebookLM. The AI-produced...
US Biopharma Industry Faces Regulatory and Financial Shifts
The ongoing budget bill debates in Congress include significant impacts on biopharma, featuring reforms to the Inflation Reduction Act that affect orphan drugs and price negotiation exemptions....
23andMe Sold to Nonprofit Led by Co-Founder in Competitive Bid
Anne Wojcicki, co-founder and former CEO of 23andMe, outbid Regeneron by securing the company's assets in a $305 million purchase through her nonprofit TTAM Research Institute. The deal ensures...
FDA Approves Checkpoint Inhibitor Pembrolizumab for Head and Neck Cancer
The FDA granted approval to pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, following the KEYNOTE-689 phase 3 trial. The...
Rapid Generation of Vascular Organoids Enhances Regenerative Medicine Potential
Researchers at Boston Children’s Hospital and collaborators have developed a rapid, defined method to generate vascular organoids from human induced pluripotent stem cells via simultaneous...
Anticancer Therapy Advances through Dual-Targeting CAR-T and Menin Inhibitors
Early clinical data reveal Johnson & Johnson's dual-targeting CD19/CD20 CAR-T therapy achieving up to 100% response rates in some lymphoma patients, while menin inhibitor combination therapy in...
Quantum Clocks Advance Global Time Measurement and Fundamental Physics
An international consortium conducted the largest coordinated optical clock comparison to date, spanning six countries and simultaneous operations of clocks and interlinking networks. These...
Novel Catalyst Breaks Down Persistent PFAS Chemicals at Ambient Conditions
Researchers at Goethe University Frankfurt have developed a boron-based catalyst embedded in a carbon framework that efficiently cleaves stubborn carbon–fluorine bonds in PFAS compounds at room...
Exercise Mobilizes Brain Cells Protecting Against Alzheimer’s Disease Pathology
A single-nucleus RNA sequencing study identified that physical activity modifies gene expression in Alzheimer’s disease mouse models, notably enhancing responses in microglia and...
FDA Approves UroGen’s Bladder Cancer Hydrogel Despite Adcom Vote
The FDA approved UroGen's hydrogel drug Zusduri for low-grade, intermediate-risk, non-muscle invasive bladder cancer despite a narrowly negative advisory committee vote. Clinical trial data...
BioNTech Moves to Settle Dispute, Buys CureVac for $1.25 Billion
BioNTech is acquiring CureVac in an all-stock deal valued at $1.25 billion, effectively ending prolonged patent litigation over mRNA vaccine technology. The transaction strengthens BioNTech's...
ADC Therapeutics Cuts UK R&D, Lays Off 30% Amid Pipeline Setbacks
ADC Therapeutics announced the closure of its U.K. research site, layoffs of 30% of staff, and discontinuation of several preclinical oncology programs after dropping its sole clinical candidate...
FDA Clears Urogen’s Zusduri Despite Advisory Panel Doubts
The U.S. Food and Drug Administration approved UroGen’s bladder cancer hydrogel, Zusduri, intended for low-grade, intermediate-risk, non-muscle invasive bladder cancer. Approval comes despite a...
BioNTech Acquires CureVac to Settle mRNA Patent Dispute
BioNTech has agreed to acquire CureVac in a $1.25 billion all-stock transaction, ending years of patent litigation over mRNA vaccine technology. The deal values CureVac’s shares at a 55% premium...